JP2014508782A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014508782A5 JP2014508782A5 JP2013557943A JP2013557943A JP2014508782A5 JP 2014508782 A5 JP2014508782 A5 JP 2014508782A5 JP 2013557943 A JP2013557943 A JP 2013557943A JP 2013557943 A JP2013557943 A JP 2013557943A JP 2014508782 A5 JP2014508782 A5 JP 2014508782A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- antibody
- tumor
- estrogen receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161451848P | 2011-03-11 | 2011-03-11 | |
| US61/451,848 | 2011-03-11 | ||
| US201261604281P | 2012-02-28 | 2012-02-28 | |
| US61/604,281 | 2012-02-28 | ||
| PCT/US2012/028792 WO2012125573A2 (en) | 2011-03-11 | 2012-03-12 | Use of inhibitors of egfr-family receptors in the treatment of hormone refractory breast cancers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014508782A JP2014508782A (ja) | 2014-04-10 |
| JP2014508782A5 true JP2014508782A5 (enExample) | 2015-04-30 |
Family
ID=45894680
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013557943A Pending JP2014508782A (ja) | 2011-03-11 | 2012-03-12 | ホルモン不応性乳癌の治療におけるｅｇｆｒファミリー受容体の阻害剤の使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20140134170A1 (enExample) |
| EP (1) | EP2683741A2 (enExample) |
| JP (1) | JP2014508782A (enExample) |
| KR (1) | KR20140044796A (enExample) |
| CN (1) | CN103562226A (enExample) |
| AU (1) | AU2012229147B2 (enExample) |
| BR (1) | BR112013022882A2 (enExample) |
| CA (1) | CA2828075A1 (enExample) |
| EA (1) | EA201300996A1 (enExample) |
| MX (1) | MX2013010379A (enExample) |
| SG (1) | SG192844A1 (enExample) |
| WO (1) | WO2012125573A2 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG178789A1 (en) * | 2007-02-16 | 2012-03-29 | Merrimack Pharmaceuticals Inc | Antibodies against erbb3 and uses thereof |
| KR101798679B1 (ko) | 2010-03-11 | 2017-11-16 | 메리맥 파마슈티컬즈, 인크. | ３중 음성 및 기저형 유방암 치료 시의 ｅｒｂｂ３ 저해제의 용도 |
| US9155802B2 (en) | 2010-11-01 | 2015-10-13 | Symphogen A/S | Pan-HER antibody composition |
| HK1202431A1 (en) | 2012-05-02 | 2015-10-02 | Symphogen A/S | Humanized pan-her antibody compositions |
| EP3087394A2 (en) | 2013-12-27 | 2016-11-02 | Merrimack Pharmaceuticals, Inc. | Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies |
| EP3786186A1 (en) | 2014-02-28 | 2021-03-03 | Merus N.V. | Antibodies that bind egfr and erbb3 |
| SMT202500020T1 (it) | 2014-02-28 | 2025-03-12 | Merus Nv | Anticorpo che lega erbb-2 ed erbb-3 |
| CN111956653B (zh) * | 2014-05-08 | 2023-06-30 | 上海市生物医药技术研究院 | 双炔失碳酯组合物和疾病治疗方法 |
| AU2016248329A1 (en) | 2015-04-17 | 2017-11-09 | Merrimack Pharmaceuticals, Inc. | Combination treatments with seribantumab |
| US10184006B2 (en) | 2015-06-04 | 2019-01-22 | Merrimack Pharmaceuticals, Inc. | Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors |
| ITUB20160828A1 (it) * | 2016-02-18 | 2017-08-18 | Univ Degli Studi Genova | Utilizzo di una dieta che mima il digiuno per potenziare l'efficacia di antiestrogeni nella terapia del cancro |
| AU2017235450A1 (en) * | 2016-03-15 | 2018-08-16 | Merrimack Pharmaceuticals, Inc. | Methods for treating ER+, HER2-, HRG+ breast cancer using combination therapies comprising an anti-ErbB3 antibody |
| NZ752443A (en) | 2016-10-11 | 2022-11-25 | Univ Duke | Lasofoxifene treatment of er+ breast cancer |
| US10624874B2 (en) | 2017-01-10 | 2020-04-21 | Zhejiang Jiachi Development Pharmaceuticals Ltd | Lasofoxifene modulation of membrane-initiated estrogen signals and methods for tumor treatment |
| US11780925B2 (en) | 2017-03-31 | 2023-10-10 | Merus N.V. | ErbB-2 and ErbB3 binding bispecific antibodies for use in the treatment of cells that have an NRG1 fusion gene |
| US12195551B2 (en) * | 2017-05-17 | 2025-01-14 | Merus N.V. | Combination of an ErbB-2/ErbB-3 bispecific antibody with endocrine therapy for breast cancer |
| SI3665198T1 (sl) | 2017-08-09 | 2025-06-30 | Merus N.V. | Protitelesa, ki vežejo egfr in cmet |
| WO2019185164A1 (en) | 2018-03-29 | 2019-10-03 | Hummingbird Bioscience Holdings Pte. Ltd. | Her3 antigen-binding molecules |
| CN117771239A (zh) | 2018-04-10 | 2024-03-29 | 杜克大学 | 乳腺癌的拉索昔芬治疗 |
| TW202227504A (zh) * | 2020-10-15 | 2022-07-16 | 大陸商上海翰森生物醫藥科技有限公司 | 抗ｅｒｂｂ３抗體或其抗原結合片段及其醫藥用途 |
| GB202116903D0 (en) | 2021-11-18 | 2022-01-05 | Sermonix Pharmaceuticals Inc | Lasofoxifene treatment of aromatase-resistant er+ cancer |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5183884A (en) | 1989-12-01 | 1993-02-02 | United States Of America | Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| DE69638269D1 (de) | 1995-06-14 | 2010-11-18 | Univ California | Hochaffine humane antikörper gegen tumorantigene |
| US5968511A (en) | 1996-03-27 | 1999-10-19 | Genentech, Inc. | ErbB3 antibodies |
| US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
| US7390632B2 (en) | 1999-09-30 | 2008-06-24 | Tumor Biology Investment Group, Inc. | Soluble ErbB3 receptor isoforms |
| US7612042B2 (en) | 2001-05-31 | 2009-11-03 | Tumor Biology Investment Group, Inc. | Methods for inhibiting heregulin and treating cancer |
| EP1283053A1 (en) | 2001-08-09 | 2003-02-12 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Inhibitors of HER3 activity |
| US7919098B2 (en) | 2002-03-26 | 2011-04-05 | Zensun ( Shanghai ) Sci & Tech Co., Ltd. | ErbB-3 based methods and compositions for treating neoplasms |
| US7332580B2 (en) | 2002-04-05 | 2008-02-19 | The Regents Of The University Of California | Bispecific single chain Fv antibody molecules and methods of use thereof |
| US7332585B2 (en) * | 2002-04-05 | 2008-02-19 | The Regents Of The California University | Bispecific single chain Fv antibody molecules and methods of use thereof |
| AR056857A1 (es) | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
| SG178789A1 (en) | 2007-02-16 | 2012-03-29 | Merrimack Pharmaceuticals Inc | Antibodies against erbb3 and uses thereof |
| NZ597466A (en) | 2007-03-01 | 2013-08-30 | Symphogen As | Recombinant anti-epidermal growth factor receptor antibody compositions |
| NZ581201A (en) | 2007-05-11 | 2012-05-25 | Enzon Pharmaceuticals Inc | Rna antagonist compounds for the modulation of her3 |
| BRPI0911652A2 (pt) | 2008-04-11 | 2015-08-04 | Merrimack Pharmaceuticals Inc | Ligantes de albumina sérica humana e seus conjugados |
| WO2010019952A2 (en) | 2008-08-15 | 2010-02-18 | Merrimack Pharmaceuticals, Inc. | Methods, systems and products for predicting response of tumor cells to a therapeutic agent and treating a patient according to the predicted response |
| CN102282168A (zh) | 2008-11-18 | 2011-12-14 | 梅里麦克制药股份有限公司 | 人血清白蛋白接头以及其结合物 |
| SG10201402742YA (en) | 2009-03-20 | 2014-08-28 | Genentech Inc | Bispecific anti-her antibodies |
| WO2010127181A1 (en) | 2009-04-29 | 2010-11-04 | Trellis Bioscience, Inc. | Improved antibodies immunoreactive with heregulin-coupled her3 |
| WO2011047180A1 (en) * | 2009-10-14 | 2011-04-21 | Merrimack Pharmaceuticals, Inc. | Bispecific binding agents targeting igf-1r and erbb3 signalling and uses thereof |
| KR101798679B1 (ko) * | 2010-03-11 | 2017-11-16 | 메리맥 파마슈티컬즈, 인크. | ３중 음성 및 기저형 유방암 치료 시의 ｅｒｂｂ３ 저해제의 용도 |
| US8481687B2 (en) | 2010-04-09 | 2013-07-09 | Aveo Pharmaceuticals, Inc. | Anti-ErbB3 antibodies |
| PH12013500064A1 (en) * | 2010-07-09 | 2013-03-11 | Exelixis Inc | Combinations of kinase inhibitors for the treatment of cancer |
-
2012
- 2012-03-12 BR BR112013022882A patent/BR112013022882A2/pt not_active IP Right Cessation
- 2012-03-12 SG SG2013062856A patent/SG192844A1/en unknown
- 2012-03-12 JP JP2013557943A patent/JP2014508782A/ja active Pending
- 2012-03-12 KR KR1020137026392A patent/KR20140044796A/ko not_active Withdrawn
- 2012-03-12 MX MX2013010379A patent/MX2013010379A/es unknown
- 2012-03-12 EA EA201300996A patent/EA201300996A1/ru unknown
- 2012-03-12 US US14/004,598 patent/US20140134170A1/en not_active Abandoned
- 2012-03-12 EP EP12711080.7A patent/EP2683741A2/en not_active Withdrawn
- 2012-03-12 AU AU2012229147A patent/AU2012229147B2/en not_active Ceased
- 2012-03-12 CA CA2828075A patent/CA2828075A1/en not_active Abandoned
- 2012-03-12 CN CN201280012969.XA patent/CN103562226A/zh active Pending
- 2012-03-12 WO PCT/US2012/028792 patent/WO2012125573A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Scagliotti et al. | The role of the insulin-like growth factor signaling pathway in non-small cell lung cancer and other solid tumors | |
| Prenen et al. | Role of targeted agents in metastatic colorectal cancer | |
| US9518130B2 (en) | Use of ERBB3 inhibitors in the treatment of triple negative and basal-like breast cancers | |
| AU2012229147B2 (en) | Use of inhibitors of EGFR-family receptors in the treatment of hormone refractory breast cancers | |
| JP6829193B2 (ja) | がんを治療するための単独または併用療法におけるｃｃｒ５拮抗剤の使用 | |
| JP2023502585A (ja) | 癌の治療のための、ＰＤ－１、ＴＧＦβ、及びＴＩＧＩＴの組み合わせ阻害 | |
| JP2019517498A (ja) | 再発性小細胞肺癌の処置方法において使用するための抗ｐｄ−１抗体 | |
| CA3060407A1 (en) | Treatment of her2 positive cancers | |
| EP3553083A1 (en) | Combination therapy for the treatment of ovarian cancer | |
| JP2017534574A (ja) | チロシンキナーゼ阻害薬（ｔｋｉ）に耐性のがんを処置するための組成物および方法 | |
| AU2010236818B2 (en) | Combination therapy using an anti-EGFR agent(s) and IGF-1R specific inhibitors | |
| JP2022502399A5 (enExample) | ||
| KR20240093915A (ko) | 모수네투주맙 및 레날리도마이드를 이용한 재발성/불응성 소포 림프종의 치료 방법 | |
| WO2017176565A1 (en) | Combinations of an anti-b7-h1 antibody and a cxcr4 peptide antagonist for treating a solid tumor | |
| JP6712226B2 (ja) | エキセメスタン及びエベロリムスと組み合わせてインスリン様成長因子（ｉｇｆ）受容体アンタゴニストを用いる癌治療 | |
| WO2022103905A1 (en) | Methods and compositions comprising a krasg12c inhibitor and a vegf inhibitor for treating solid tumors | |
| JP2026079825A (ja) | 癌の治療のための、ＰＤ－１、ＴＧＦβ、及びＴＩＧＩＴの組み合わせ阻害 | |
| JP2024511995A (ja) | がん治療における第一選択療法としてのｓＥｐｈＢ４－ＨＳＡ融合タンパク質の使用 | |
| WO2023230429A1 (en) | Methods of treating colorectal cancer with tucatinib in combination with an anti-her2 antibody | |
| TWI500630B (zh) | 具有細胞生長抑制功效之表皮生長因子受體（ｅｇｆｒ）抑制劑類及彼等於腫瘤治療上之用途 | |
| NZ614427B2 (en) | Use of inhibitors of egfr-family receptors in the treatment of hormone refractory breast cancers | |
| Shabaya et al. | Novel therapeutic strategies and combinations for HER2-overexpressing breast cancer |